Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Orion Oyj - Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
GlobeNewswire

Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market Orion Pharma (“Orion”) and Shilpa Biologicals Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited…

forbes.com - Ed Garibian - Why Modern Pharma Requires A Central Nervous System For Assets
Why Modern Pharma Requires A Central Nervous System For Assets
Forbes

Ed Garibian, LLumin CEO and software entrepreneur, has 35 years of experience in machine maintenance, asset management & IoT technologies. Within manufacturing environments, equipment breakdown is an expensive inconvenience. In pharma, it is a…

globenewswire.com - Zealand Pharma - Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
GlobeNewswire

Company announcement No. 28 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 26, 2026) Copenhagen, Denmark, June 29, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL)…

fool.com - Motley Fool Staff - Big Pharma Has a Case of Merger Mania
Big Pharma Has a Case of Merger Mania
The Motley Fool

In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Tyler Crowe, Matt Frankel, and Lou Whiteman take a dive into what's driving the merger-and-acquisition frenzy, including: Big pharma is using big wallets for M&A. Who's…

afr.com - Joshua Peach - One Nation's new MP owns five properties, pharma stocks
One Nation's new MP owns five properties, pharma stocks
Australian Financial Review

One Nation's newly elected federal MP David Farley has disclosed a raft of financial interests, including stakes in obscure ASX-listed stocks, trading accounts and an expansive property portfolio. Under current lower house guidelines, all MPs must…

thehindubusinessline.com - Aurobindo Pharma completes acquisition of US-based Lannett Company
Aurobindo Pharma completes acquisition of US-based Lannett Company
BusinessLine

, an arm of Aurobindo Pharma, completed the previously announced acquisition of Lannett Company, Inc., USA from Lannett Seller Holdco, Inc. On June 18, 2026, Aurobindo received approval from the US Federal Trade Commission for the acquisition.

thehindubusinessline.com - CCI closes anti-competitive practices case against druggists' body, pharma companies
CCI closes anti-competitive practices case against druggists' body, pharma companies
BusinessLine

Fair trade regulator CCI on Monday closed a long-running probe into alleged anti-competitive practices against AIOCD, its affiliated associations and several pharma companies, after finding no violation of competition law. The case pertained to…

scmp.com - Julie Zhang - Hong Kong draws royalties giant as mainland China biotech licensing heats up
Hong Kong draws royalties giant as mainland China biotech licensing heats up
South China Morning Post

The world's largest buyer of biopharmaceutical royalties has set up its first Asia-Pacific base in Hong Kong, joining a string of multinational corporations in the pharmaceutical sector establishing offices in the city as out-licensing deals by…

jpost.com - JERUSALEM POST STAFF - Israeli health-tech conference opens in Jerusalem with 1,800 participants
Israeli health-tech conference opens in Jerusalem with 1,800 participants
The Jerusalem Post

The Israel Advanced Technology Industries (IATI) opened MIXiii Health-Tech.IL 2026 in Jerusalem on Monday, bringing roughly 1,800 participants and representatives from more than 40 countries to the International Convention Center, organizers said.

seekingalpha.com - Edmund Ingham - BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO)
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO)
Seeking Alpha

BridgeBio Pharma, Inc. remains a Buy, driven by Attruby's commercial launch and a robust late-stage pipeline targeting rare genetic diseases. BBIO's $14bn+ valuation is underpinned by four potential blockbuster drugs by 2030, with key NDA catalysts…

ourrevolution.com - Our Revolution - Ro Khanna for Re-Election to Congress - Our Revolution
Ro Khanna for Re-Election to Congress - Our Revolution
HOME - Our Revolution

For nearly a decade in Congress, Rep. Ro Khanna has proven that bold progressive leadership can deliver real results. That's why Our Revolution is proud to endorse Ro Khanna for re-election to represent California's 17th Congressional District. Ro…

cnbc.com - Elsa Ohlen - French biotech stock soars 31% after new data on experimental medicine
French biotech stock soars 31% after new data on experimental medicine
CNBC

The late-stage clinical trial data of the medicine, released late on Monday, showed that malignancies were in line with expected background rates. Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug…

seekingalpha.com - High Alpha Professor - Micron And The Price Of Certainty (NASDAQ:MU)
Micron And The Price Of Certainty (NASDAQ:MU)
Seeking Alpha

Micron Technology, Inc. shifts to a partially contracted business model, with SCAs covering over half of future revenue and improving visibility. SCAs provide downside protection via floor prices but limit upside with ceilings, complicating…

thehill.com - Nathaniel Weixel - PBM lobby goes on the offensive
PBM lobby goes on the offensive
The Hill

The nation's top pharmacy benefit manager (PBM) lobbying group is going on the offensive, stepping up its advocacy efforts against the pharmaceutical industry after Congress passed a PBM industry overhaul last winter. The pharmaceutical industry…

seekingalpha.com - Wolf Report - Danaher: Why I'm Not Paying 24x P/E For 8% EPS Growth (NYSE:DHR)
Danaher: Why I'm Not Paying 24x P/E For 8% EPS Growth (NYSE:DHR)
Seeking Alpha

Danaher (DHR) is a high-quality life sciences holding company, but current valuation does not justify a buy. DHR's reliance on M&A and exposure to pharma spending cycles pose risks, with organic growth slowing to just above 4% AEPS in 2025. Despite…

Receive a Daily briefing on Pharma Industry News

Get Started